Pembrolizumab-Associated Cardiotoxicity: A Retrospective Analysis of the FDA Adverse Events Reporting System.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) have been successfully used in the previous decade for the treatment of a variety of malignancies. Adverse events (AEs) can cause many symptoms, most notably cardiac. We analyzed the frequency of these adverse events, comparing pembrolizumab and other ICIs.

Methods

Using the Food and Drug Administration (FDA) adverse event reporting database (FAERS), we searched for all adverse events of interest reported for every ICI included in this study. After obtaining the data, we conducted a disproportionality analysis using the reporting odds ratio (ROR) and the information component (IC).

Results

A total of 6719 ICI-related cardiac adverse events of interest were reported in the database. Serious outcomes were reported in 100% o

SUBMITTER: Milutinovic S 

PROVIDER: S-EPMC11510316 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature